Home> Products> personalized treatment plans

{ "products": [ { "_id": "6948f4ee5837f90c86a7e578", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Elagolix 200mg ", "description": "Eligolux200 contains 200 mg of elagolix per tablet and is manufactured by Steris Healthcare Pvt Ltd in India as a prescription medication in packs of 3x10 tablets. Elagolix acts as a potent gonadotropin-releasing hormone (GnRH) receptor antagonist, binding competitively to GnRH receptors in the pituitary gland to rapidly reduce estrogen and progesterone levels without the initial flare-\nup seen in agonists. This mechanism starves endometrial-like tissue outside the uterus of hormonal stimulation, shrinking lesions and easing inflammation.\n\nAdminister Eligolux200 orally, swallowed whole with water, with or without food, typically starting within 7 days of menstrual onset. Standard dosing for severe cases involves 200mg twice daily for up to 6 months, or 150mg once daily extended to 24 months, adjusted by physicians based on tolerance and response. Store in a cool, dry place away from moisture and light, keeping out of children's reach.\n\nPrimary Uses\nEligolux200 targets moderate to severe endometriosis-associated pain, including dysmenorrhea (painful periods), nonmenstrual pelvic pain, and dyspareunia (painful intercourse). Endometriosis affects millions globally, causing tissue similar to the uterine lining to grow ectopically, leading to chronic inflammation, adhesions, and scarring. By dosing flexibly, Eligolux200 suits patients needing stronger suppression for intense symptoms, reducing reliance on opioids or surgery.\n\nClinical trials like Elaris EM-I and EM-II showed 75% dysmenorrhea reduction and 50-60% nonmenstrual pain relief at 6-12 months. It also curbs heavy menstrual bleeding in uterine fibroids, offering dual benefits for overlapping conditions. Physicians prescribe it when first-line NSAIDs or oral contraceptives fail, prioritizing non-invasive symptom control.\n​\n\nKey Benefits\nEligolix in Eligolux200 delivers rapid pain relief, with significant improvements in daily pain scales within 3 months versus placebo. Women report 47% better composite pelvic pain scores, enhancing daily activities, work productivity, and intimacy. Quality-of-life metrics improve consistently over 24 weeks, including reduced fatigue and better emotional well-being.\n​\n\nUnlike injectables, its oral form and dose-dependent estrogen suppression allow titration—lower doses minimize hypoestrogenic effects while higher 200mg dosing tackles severe pain. Studies confirm amenorrhea in 25% of users early on, slashing bleeding days by up to 50%. Long-term data up to 12 months with add-back therapy sustains efficacy, preserving bone health better than monotherapy. Patients regain control, avoiding invasive laparoscopies and reclaiming normalcy.\n​\n\nBenefit\tEvidence from Trials'\tImpact on Patients\nDysmenorrhea Reduction:\t75% at 6 months \n​\tFewer missed workdays\nNonmenstrual Pain Relief:\t50-60% improvement \n​\tEnhanced mobility\nBleeding Control:\t14% bleeding days vs. 24% baseline \n​\tImproved hygiene, anemia prevention\nQuality of Life\tSustained over 24 weeks \n​\tBetter sleep, relationships\nPotential Side Effects\nCommon side effects of Eligolux200 mirror hypoestrogenic states: hot flashes, night sweats, headache, and nausea, each affecting about 10% of users. These often lessen as the body adjusts, with 69.5% overall adverse event rate over 24 weeks, mostly mild. Mood changes like irritability or depression occur less commonly, warranting mood monitoring.\n​\n\nBone mineral density (BMD) loss poses a key concern—200mg twice daily causes -1.5% to -2.4% drops at lumbar spine and hip after 6 months, attenuated with calcium/vitamin D or add-back therapy. Rare serious risks include suicidal thoughts, liver enzyme elevations, or allergic reactions like anaphylaxis. Discontinuation due to events stays low at 4-12%. No deaths are linked directly to treatment in trials.\n​\n\nSide Effect Category\tFrequency\tManagement\nVasomotor (Hot Flashes)\t9.9-10% \n​\tLifestyle cooling, dose adjustment\nNeurologic (Headache)\t9.9% \n​\tHydration, analgesics\nBone Loss\tUp to 2.4% at 6 months \n​\tDEXA scans, supplements\nMood Changes\tLess common \n​\tPsychiatric screening\nPrecautions and Contraindications\nAvoid Eligolux200 in pregnancy (risk of early loss), known osteoporosis, severe hepatic impairment, or with strong OATP1B1 inhibitors like cyclosporine or gemfibrozil. Women of childbearing age need effective non-hormonal contraception during and 28 days post-therapy, as it impairs recognition of pregnancy via amenorrhea. Not for pediatrics under 18 or geriatrics lacking data.\n\nScreen for depression history, liver function, and BMD before starting; monitor quarterly. Drug interactions abound with rifampin (reduces levels) or over 50 others like clarithromycin—inform physicians fully. Breastfeeding lacks safety data; weigh risks. Regular blood/urine tests track efficacy and safety.\n​\n\nDosage Guidelines\nInitiate Eligolux200 at 150mg daily for milder cases, escalating to 200mg BID for dyspareunia or severe pain, max 6 months at higher dose. Miss a dose? Take promptly unless near the next; never double. Duration caps at 24 months total, with liver-adjusted lower dosing. Pair with add-back for extended use to curb BMD loss.\n​\n\nPhysicians tailor based on response: 74-77% complete 6-month trials. Swallow intact; no crushing.\n​\n\nClinical Evidence\nPhase III trials (Elaris EM-I/II) randomized 1689 women, proving both doses superior to placebo for co-primary endpoints of dysmenorrhea and nonmenstrual pain. Open-label extensions to 24 weeks maintained gains. A 12-month study with add-back showed persistent relief and <1% additional BMD loss versus placebo. Real-world use echoes this, positioning Eligolix as first oral GnRH antagonist approved for endometriosis.\n​\n\nVersus relugolix, Eligolix offers comparable pelvic pain reduction with adjustable dosing. Indian brands like Eligolux200 align with global standards.\n​\n\nConclusion\nEligolux200 transforms endometriosis management, delivering substantial pain relief and functional gains through precise hormonal control. Balancing robust benefits against manageable risks like BMD monitoring empowers women toward symptom-free lives. Consult healthcare providers for personalized integration into care plans.\n", "price": 1000.0, "discountamount": 300.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2251, "imageuri": "https://productimages.withfloats.com/actual/694a2b9f403179ac7e958ef6.png", "tileimageuri": "https://productimages.withfloats.com/tile/694a2b9f403179ac7e958ef6.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-12-22T07:36:14.316Z", "updatedon": "2026-03-26T06:00:31.59Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/elagolix-200mg-/2251", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "ELIGOLUX 200", "category": "GYANECOLOGYRANGE", "tags": [ "Elagolix Tablets 200mg", "Elagolix acts as a potent gonadotropin-releasing hormone.", "nonmenstrual pelvic pain.", "adhesions, and scarring", "preserving bone health better than monotherapy.", "avoiding invasive laparoscopies and reclaiming normalcy.", "pituitary gland to rapidly reduce estrogen and progesterone.", "tab elagolix 200mg", "elagolix 200mg.", "elagolix.", "elagolix 200.", "elagolix tablets", "elagolix tablets uses.", "elagolix 200 mg price.", "elagolix mechanism of action.", "elagolix 200 mg uses.", "tab elagolixtab elagolix." ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6943af86161ad9de85f42b10", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "imatinib 400mg", "description": "IMATIFLOW 400, containing Imatinib IP 400mg, represents a breakthrough in targeted cancer therapy, offering patients a precise weapon against specific malignancies. This oral medication belongs to the class of tyrosine kinase inhibitors, revolutionizing treatment for conditions once deemed challenging to manage. By blocking abnormal proteins that fuel cancer cell growth, IMATIFLOW 400 helps restore normal cellular function and improves quality of life for many users.​\n\nProduct Overview\nIMATIFLOW 400 is a branded formulation of Imatinib mesylate 400mg, produced to high pharmaceutical standards for consistent efficacy and bioavailability. Each tablet delivers the active ingredient in a film-coated form, designed for once-daily administration with food to enhance absorption and minimize gastrointestinal upset. Developed for adult patients, it targets cancers driven by dysregulated tyrosine kinases like BCR-ABL, c-KIT, and PDGFR, making it a cornerstone in modern oncology protocols.​\n\nThe medication's mechanism hinges on competitive inhibition at the ATP-binding site of these kinases, halting downstream signaling pathways that promote uncontrolled proliferation, survival, and metastasis of malignant cells. Unlike traditional chemotherapy, which broadly attacks dividing cells, IMATIFLOW 400 spares most healthy tissues, leading to a more favorable safety profile. Clinical data from pivotal trials underscore its role as first-line therapy, with high response rates observed within months of initiation.​\n\nPrimary Uses\nIMATIFLOW 400 excels in treating chronic myeloid leukemia (CML), particularly in the chronic phase where it induces deep molecular responses in over 80% of patients. It suppresses the Philadelphia chromosome-positive cells hallmark of CML by inhibiting the BCR-ABL fusion protein, dramatically extending progression-free survival. For newly diagnosed patients, standard dosing starts at 400mg daily, often achieving complete cytogenetic remission.​\n\nIn gastrointestinal stromal tumors (GIST), IMATIFLOW 400 targets KIT or PDGFRA mutations, shrinking unresectable tumors and delaying progression in advanced cases. The recommended dose remains 400mg once daily, with potential escalation to 600-800mg for resistant strains, as per oncology guidelines. It also finds application in dermatofibrosarcoma protuberans (DFSP), aggressive systemic mastocytosis, and certain myelodysplastic syndromes, broadening its utility in precision medicine.​\n\nHealthcare providers monitor response via PCR for BCR-ABL transcripts in CML or imaging for GIST, adjusting therapy based on milestones like major molecular response. Patients with Ph+ acute lymphoblastic leukemia (ALL) may receive it adjunctively, enhancing outcomes when combined with chemotherapy. Overall, IMATIFLOW 400 transforms these diseases from fatal to chronically manageable.​\n\nKey Benefits\nOne standout benefit of IMATIFLOW 400 is its oral convenience, eliminating the need for frequent hospital visits associated with infusions. Response rates exceed 90% in early CML, with many patients achieving treatment-free remission after sustained deep responses, a paradigm shift from interferon-era therapies.​\n\nTumor control in GIST prevents life-threatening complications like bowel obstruction, improving survival from months to years. Its specificity reduces severe toxicities, allowing patients to maintain daily activities, work, and social engagements with minimal disruption. Long-term studies report 10-year survival rates above 80% in CML, underscoring durable efficacy.​\n\nAdditional advantages include cost-effectiveness over biologics and compatibility with supportive care like hydroxyurea for cytoreduction. Fluid retention, while common, responds well to diuretics, preserving cardiac function. For Indian patients, accessible pricing via brands like IMATIFLOW 400 supports equitable care in resource-limited settings.​\n\nPotential Side Effects\nWhile generally well-tolerated, IMATIFLOW 400 can cause edema (swelling in legs or face) in up to 70% of users, managed by dose reduction or supportive measures. Gastrointestinal issues like nausea, vomiting, and diarrhea affect 40-50%, often resolving with antiemetics and dietary adjustments.​\n\nMusculoskeletal pain, cramps, and fatigue occur frequently, alongside rash and abdominal discomfort. Hematologic effects include neutropenia or thrombocytopenia, necessitating regular blood counts. Rare but serious risks involve liver enzyme elevation, heart failure, or hemorrhage; prompt reporting of symptoms like shortness of breath or yellowing skin is crucial.​\n\nAvoid grapefruit juice, as it elevates drug levels, and inform doctors of concurrent medications like CYP3A4 inhibitors. Pregnancy category D status advises contraception, with monitoring for growth retardation in exposed fetuses. Dizziness may impair driving, so caution is essential during initial weeks.​\n\nDosage and Administration Guidelines\nSwallow IMATIFLOW 400 whole with a meal and full glass of water to optimize pharmacokinetics and reduce esophageal irritation. The standard adult dose for CML chronic phase is 400mg daily; for accelerated phase or blast crisis, 600mg. GIST dosing mirrors 400mg, titrated based on tolerance and response.​\n\nRenal or hepatic impairment requires dose adjustments—reduce to 300-400mg in moderate cases. Do not crush or chew tablets. Missed doses should be taken promptly unless near the next, avoiding doubles. Long-term use demands quarterly monitoring of CBC, liver function, and ECG.​\n\nPrecautions and Interactions\nPatients with a cardiac history need baseline echocardiograms, as QT prolongation or effusion risks exist. Drug interactions abound: St. John's wort induces metabolism, reducing efficacy; ketoconazole boosts levels. Vaccines, especially live ones, are contraindicated during therapy.​\n\nRegular dermatologic checks mitigate skin cancer risk from prolonged use. Hydration combats fluid retention, and low-salt diets aid management. Steris Healthcare emphasizes patient education via counseling on adherence for optimal outcomes.​\n\nConclusion\nIMATIFLOW 400 (Imatinib IP 400mg) stands as a testament to targeted therapy's power, offering robust control over CML, GIST, and related cancers with a balance of efficacy and manageability. Its benefits in prolonging life and enhancing daily functioning far outweigh transient side effects for most when monitored diligently. Consult oncologists for personalized plans, ensuring this innovative treatment maximizes hope and health in the fight against cancer.", "price": 1827.0, "discountamount": 540.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2249, "imageuri": "https://productimages.withfloats.com/actual/6943b026ca1b0dcfc6c37820.png", "tileimageuri": "https://productimages.withfloats.com/tile/6943b026ca1b0dcfc6c37820.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-12-18T07:38:46.766Z", "updatedon": "2026-04-15T10:27:12.329Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//imatinib-400mg/2249", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "IMATIFLOW 400", "category": "NEPHROLOGYRANGE", "tags": [ "Imatinib IP 400mg", "offering robust control over CML.", "related cancers with a balance of efficacy and manageability.", "innovative treatment maximizes hope and health in the fight against cancer.", "cancer therapy.", "fuel cancer cell growth.", "chemotherapy.", "imatinib 400mg.", "imatinib 400mg tablet.", "tab. imatinib 400mg.", "imatinib 400mg price.", "imatinib 400mg tab", "imatinib 400mg side effects.", "imatinib 400 mg tablet", "imatinib 400 mg medicine", "imatinib tablets 400 mg uses", "imatinib 400 mg dosage", "imatinib 400 mg price in india", "imatinib 400 mg brand name" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "668e8611b9f7300708fe1240", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TRIOGLIMITERIS 1/0.2 ", "description": "TRIOGLIMITERIS 1/0.2 \nVoglibose 0.2 mg, Glimepiride 1 mg & Metformin Hydrochloride 500 mg\nIntroduction\n\nTRIOGLIMITERIS 1/0.2 is a combination medication containing Voglibose, Glimepiride, and Metformin Hydrochloride. It is primarily used in the management of type 2 diabetes mellitus to improve glycemic control through different mechanisms of action targeting glucose metabolism.\n\nComposition\n\nVoglibose (0.2 mg): An alpha-glucosidase inhibitor that delays the digestion of carbohydrates in the intestine, thereby reducing postprandial blood glucose levels.\nGlimepiride (1 mg): A sulfonylurea derivative that stimulates insulin release from pancreatic beta cells, enhancing glucose uptake in peripheral tissues.\nMetformin Hydrochloride (500 mg): A biguanide that decreases hepatic glucose production, improves insulin sensitivity in peripheral tissues, and reduces intestinal glucose absorption.\nMechanism of Action\n\nTRIOGLIMITERIS 1/0.2 combines the actions of its components to achieve optimal glycemic control:\n\nVoglibose: Inhibits alpha-glucosidase enzymes in the intestine, delaying carbohydrate digestion and reducing the absorption of glucose after meals.\nGlimepiride: Stimulates insulin secretion from pancreatic beta cells in a glucose-dependent manner, thereby lowering blood glucose levels.\nMetformin Hydrochloride: Decreases hepatic glucose production through suppression of gluconeogenesis and enhances peripheral glucose uptake and utilization by improving insulin sensitivity.\nIndications\n\nTRIOGLIMITERIS 1/0.2 is indicated for:\n\nType 2 Diabetes Mellitus: Used to improve glycemic control in adults when diet, exercise, and monotherapy with metformin or sulfonylureas alone are not sufficient.\nDosage and Administration\n\nThe typical dosage of TRIOGLIMITERIS 1/0.2 is one tablet taken orally with meals, usually once or twice daily.\nDosage adjustments may be required based on individual patient response, blood glucose levels, and renal function.\nIt is essential to adhere to the prescribed dosage regimen to achieve optimal therapeutic outcomes.\nSide Effects\n\nCommon side effects of TRIOGLIMITERIS 1/0.2 may include:\n\nHypoglycemia (especially when used in combination with insulin or other antidiabetic medications)\nGastrointestinal disturbances (such as nausea, vomiting, diarrhea, or abdominal discomfort)\nWeight gain (mainly associated with sulfonylureas)\nMore severe side effects can include:\n\nAllergic reactions (rash, itching, swelling)\nLactic acidosis (rare but serious adverse effect associated with metformin use)\nHepatic dysfunction (monitor liver function tests periodically)\nPrecautions\n\nUse with caution in patients with renal impairment, hepatic dysfunction, or other significant medical conditions that may affect drug metabolism or excretion.\nRegular monitoring of blood glucose levels, renal function, and liver function is recommended during treatment with TRIOGLIMITERIS 1/0.2.\nAvoid use in patients with type 1 diabetes mellitus or diabetic ketoacidosis.\nDrug Interactions\n\nTRIOGLIMITERIS 1/0.2 may interact with other medications affecting blood glucose levels, such as insulin, other oral antidiabetic agents, or drugs that affect renal function or hepatic metabolism. Close monitoring and dose adjustments may be necessary.\nConclusion\n\nTRIOGLIMITERIS 1/0.2 provides a comprehensive approach to managing type 2 diabetes mellitus by combining Voglibose, Glimepiride, and Metformin Hydrochloride. This combination targets different aspects of glucose metabolism, enhancing insulin secretion, reducing hepatic glucose production, and delaying carbohydrate absorption in the intestine. Proper dosage, administration, and monitoring for side effects are essential to achieve and maintain optimal glycemic control in diabetic patients using TRIOGLIMITERIS 1/0.2. Consultation with a healthcare provider is recommended for personalized treatment plans and management of diabetes with this medication.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order NOW\n", "price": 195.0, "discountamount": 58.5, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "500 mg", "0.2 mg", "one tablet", "Weight gain", "Glimepiride 1", "metformin use", "Proper dosage", "Glimepiride (1", "dosage regimen", "typical dosage", "renal function", "insulin release", "drug metabolism", "Lactic acidosis", "Close monitoring", "dose adjustments", "renal impairment", "diabetic patients", "insulin secretion", "different aspects", "Drug Interactions", "other medications", "Regular monitoring", "Dosage adjustments", "Allergic reactions", "peripheral tissues", "hepatic metabolism", "glucose metabolism", "insulin sensitivity", "healthcare provider", "Hepatic dysfunction", "Common side effects", "abdominal discomfort", "different mechanisms", "liver function tests", "diabetic ketoacidosis", "pancreatic beta cells", "combination medication", "carbohydrate digestion", "comprehensive approach", "serious adverse effect", "Metformin Hydrochloride", "carbohydrate absorption", "sulfonylurea derivative", "glucose-dependent manner", "optimal glycemic control", "type 1 diabetes mellitus", "type 2 diabetes mellitus", "More severe side effects", "alpha-glucosidase enzymes", "peripheral glucose uptake", "hepatic glucose production", "alpha-glucosidase inhibitor", "individual patient response", "personalized treatment plans", "optimal therapeutic outcomes", "Gastrointestinal disturbances", "intestinal glucose absorption", "other antidiabetic medications", "other oral antidiabetic agents", "postprandial blood glucose levels", "other significant medical conditions" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1939, "imageuri": "https://productimages.withfloats.com/actual/668e86143a68154e11e7d822.jpeg", "tileimageuri": "https://productimages.withfloats.com/tile/668e86143a68154e11e7d822.jpeg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-07-10T13:01:05.875Z", "updatedon": "2026-03-26T05:46:52.891Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//trioglimiteris-1-0-2-/1939", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "TRIOGLIMITERIS 1/0.2 ", "category": "DIABETIC RANGE", "tags": [ "glimepiride 1mg+metformin 500mg+voglibose 0.2 mg", "Glimepiride 2mg Metformin 500mg Voglibose 0.2 mg b", "glimepiride 2mg+metformin 500mg+voglibose 0.2 mg", "voglibose glimepiride & metformin hydrochloride (s", "voglibose glimepiride + metformin hydrochloride us", "glimepiride 1mg+metformin 500mg+voglibose 0.3 mg", "glimepiride 2mg+metformin 500mg+voglibose 0.2 mg g", "" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "668e7ff07e47881008f6860e", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TRIMETAZ CR 80 ", "description": "TRIMETAZ CR 80 \nTrimetazidine (80mg)\nIntroduction\nTRIMETAZ CR 80 is a medication containing Trimetazidine hydrochloride, formulated to treat angina pectoris and certain other cardiovascular conditions. It is known for its metabolic effects on the heart muscle, improving myocardial efficiency and reducing symptoms associated with ischemic heart disease.\n\nComposition\n\nTrimetazidine (80mg): The active ingredient, Trimetazidine, acts as a cellular metabolic agent that enhances myocardial glucose utilization and improves energy production in the heart muscle.\nMechanism of Action\nTrimetazidine exerts its therapeutic effects through several mechanisms:\n\nMetabolic Regulation: Shifts myocardial energy substrate utilization from fatty acids toward glucose oxidation, which is more efficient and requires less oxygen.\nAnti-ischemic Effect: Protects the heart against ischemic damage by preserving cellular energy metabolism and reducing oxidative stress.\nImprovement in Symptomatology: Reduces angina symptoms such as chest pain, shortness of breath, and exercise intolerance by enhancing myocardial function.\nIndications\nTRIMETAZ CR 80 is indicated for:\n\nChronic Stable Angina Pectoris: Used as adjunctive therapy in patients who are inadequately controlled with other anti-anginal medications.\nIschemic Heart Disease: Helps improve myocardial function and reduce symptoms associated with coronary artery disease.\nDosage and Administration\n\nThe usual dosage of TRIMETAZ CR 80 is one tablet (80mg) taken orally twice daily, preferably with meals.\nThe extended-release formulation ensures sustained therapeutic levels of Trimetazidine throughout the day.\nDosage adjustments may be necessary based on individual patient response and tolerance.\nSide Effects\nCommon side effects may include:\n\nHeadache\nDizziness\nNausea\nGastrointestinal disturbances (such as abdominal pain or diarrhea)\nSevere side effects are rare but may include:\n\nAllergic reactions (rash, itching, swelling)\nExtrapyramidal symptoms (involuntary movements)\nHepatic dysfunction (monitor liver function tests periodically)\nPrecautions\n\nUse with caution in patients with severe renal impairment or hepatic dysfunction, as Trimetazidine metabolism may be altered.\nMonitor patients for signs of extrapyramidal symptoms, especially in patients with Parkinson's disease or other movement disorders.\nAvoid abrupt discontinuation of Trimetazidine, as it may worsen angina symptoms.\nDrug Interactions\n\nTrimetazidine may interact with other medications that affect myocardial metabolism or cardiac function, including beta-blockers and calcium channel blockers. Close monitoring is recommended when used concomitantly.\nConclusion\nTRIMETAZ CR 80 is a valuable therapeutic option for managing chronic stable angina pectoris and ischemic heart disease by improving myocardial efficiency and reducing symptoms associated with cardiac ischemia. Its mechanism of action, focusing on metabolic modulation and anti-ischemic effects, makes it an effective adjunctive therapy in patients with inadequate symptom control on standard anti-anginal medications. Proper dosage, administration, and monitoring for side effects are essential to ensure safe and effective use of TRIMETAZ CR 80 in cardiovascular patients. Consultation with a healthcare provider is recommended for personalized treatment plans and management of cardiac conditions with TRIMETAZ CR 80.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order NOW\n\n", "price": 435.0, "discountamount": 130.5, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "one tablet", "chest pain", "less oxygen", "fatty acids", "TRIMETAZ CR", "usual dosage", "heart muscle", "Proper dosage", "effective use", "abdominal pain", "angina symptoms", "ischemic damage", "Close monitoring", "cardiac ischemia", "oxidative stress", "cardiac function", "Drug Interactions", "active ingredient", "glucose oxidation", "metabolic effects", "energy production", "other medications", "Dosage adjustments", "Allergic reactions", "adjunctive therapy", "several mechanisms", "cardiac conditions", "healthcare provider", "Hepatic dysfunction", "myocardial function", "therapeutic effects", "Severe side effects", "Common side effects", "metabolic modulation", "Metabolic Regulation", "liver function tests", "involuntary movements", "anti-ischemic effects", "myocardial efficiency", "myocardial metabolism", "abrupt discontinuation", "ischemic heart disease", "Extrapyramidal symptoms", "cardiovascular patients", "coronary artery disease", "severe renal impairment", "Trimetazidine metabolism", "cellular metabolic agent", "other movement disorders", "calcium channel blockers", "cellular energy metabolism", "inadequate symptom control", "Trimetazidine hydrochloride", "valuable therapeutic option", "individual patient response", "extended-release formulation", "sustained therapeutic levels", "personalized treatment plans", "Gastrointestinal disturbances", "other anti-anginal medications", "myocardial glucose utilization", "Chronic Stable Angina Pectoris", "other cardiovascular conditions", "standard anti-anginal medications", "myocardial energy substrate utilization" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1938, "imageuri": "https://productimages.withfloats.com/actual/668e7ff3f07c99c3af8e8504.jpeg", "tileimageuri": "https://productimages.withfloats.com/tile/668e7ff3f07c99c3af8e8504.jpeg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-07-10T12:34:56.538Z", "updatedon": "2026-03-16T08:50:52.289Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//trimetaz-cr-80-/1938", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "TRIMETAZ CR 80 ", "category": "CARDIOLOGYRANGE", "tags": [ "Trimetazidine 80mg price", "Trimetazidine 35 mg uses", "Trimetazidine 80 mg brand name", "When to stop taking trimetazidine", "Trimetazidine hydrochloride extended release CAPSU", "Trimetazidine mechanism of action", "Trimetazidine 35 mg brand name", "" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "666ad72b56d62a1b8c8d620a", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Pramipexole 0.5mg", "description": "PRAMIPEXOLE 0.50\nPramipexole (0.50mg)\nIntroduction:\nPramipexole 0.5mg – Effective Support for Parkinson’s Disease and Restless Legs Syndrome\n\nNeurological disorders such as Parkinson’s disease and Restless Legs Syndrome (RLS) can significantly affect a person’s daily life, movement, sleep quality, and overall comfort. Patients dealing with tremors, stiffness, muscle control issues, or uncontrollable leg sensations often seek a reliable treatment option that can improve their quality of life. Pramipexole 0.5mg is one of the commonly prescribed medicines used to manage these symptoms effectively.\n\nPramipexole belongs to a group of medicines known as dopamine agonists. It works by mimicking the action of dopamine, a natural chemical messenger in the brain responsible for controlling movement and coordination. By improving dopamine activity, Pramipexole helps reduce symptoms associated with neurological disorders.\n\nIf you are searching for an effective medicine for Parkinson’s disease or Restless Legs Syndrome, understanding how Pramipexole 0.5mg works, its benefits, dosage, side effects, and precautions can help you make a more informed healthcare decision.\n\nWhat Is Pramipexole 0.5mg?\n\nPramipexole 0.5mg is a prescription medication mainly used to treat:\n\nParkinson’s disease\nRestless Legs Syndrome (RLS)\n\nThe medicine stimulates dopamine receptors in the brain, helping improve muscle control, movement, and coordination. Since dopamine levels are often reduced in patients with Parkinson’s disease, Pramipexole helps compensate for this deficiency.\n\nDoctors may prescribe Pramipexole alone or alongside other medications depending on the severity of symptoms and patient requirements.\n\nHow Does Pramipexole 0.5mg Work?\n\nThe brain uses dopamine to regulate smooth muscle movement and nerve signaling. In conditions such as Parkinson’s disease, dopamine-producing nerve cells gradually become damaged, leading to symptoms like tremors, stiffness, and difficulty moving.\n\nReduced Dopamine→Impaired Movement and Coordination\n\nPramipexole acts as a dopamine agonist, meaning it imitates dopamine by stimulating dopamine receptors in the brain.\n\nPramipexole→Dopamine Receptor Activation→Improved Motor Function\n\nThis action helps:\n\nReduce tremors\nImprove movement\nRelieve muscle stiffness\nEnhance balance and coordination\nMinimize uncomfortable sensations in the legs\n\nFor patients with Restless Legs Syndrome, the medicine helps calm the urge to move the legs, especially during nighttime.\n\nBenefits of Pramipexole 0.5mg\n1. Helps Manage Parkinson’s Disease Symptoms\n\nPramipexole is widely used to reduce common symptoms of Parkinson’s disease, including:\n\nTremors\nSlowed movement\nMuscle rigidity\nPoor balance\n\nBy improving dopamine activity, the medicine enhances daily functioning and mobility.\n\n2. Effective Relief for Restless Legs Syndrome\n\nPatients suffering from Restless Legs Syndrome often experience:\n\nTingling sensations\nBurning discomfort\nStrong urge to move the legs\nSleep disturbances\n\nPramipexole 0.5mg helps reduce these symptoms and supports better sleep quality.\n\n3. Improves Quality of Life\n\nConsistent symptom control allows patients to perform daily tasks more comfortably and independently.\n\n4. Supports Better Sleep\n\nFor RLS patients, reducing nighttime leg discomfort can significantly improve sleep patterns and reduce fatigue.\n\n5. Flexible Treatment Option\n\nDoctors may use Pramipexole alone or in combination with other Parkinson’s medications for personalized treatment plans.\n\nUses of Pramipexole 0.5mg\nParkinson’s Disease\n\nParkinson’s disease is a progressive neurological disorder affecting movement and coordination. Pramipexole helps control symptoms and supports improved mobility.\n\nRestless Legs Syndrome (RLS)\n\nRLS causes uncomfortable sensations and an uncontrollable urge to move the legs, especially during rest or sleep. Pramipexole helps reduce these symptoms effectively.\n\nCombination Therapy\n\nIn some cases, doctors prescribe Pramipexole with other medications such as levodopa for enhanced symptom management.\n\nDosage and Administration\n\nPramipexole should only be taken as prescribed by a healthcare professional.\n\nGeneral guidelines include:\n\nSwallow the tablet with water\nTake with or without food\nFollow the exact dosage schedule recommended by your doctor\nDo not stop the medicine suddenly without medical advice\n\nThe dosage may vary depending on:\n\nMedical condition\nSeverity of symptoms\nAge\nPatient response to treatment\n\nDoctors usually start with a lower dose and gradually increase it to minimize side effects.\n\nPossible Side Effects of Pramipexole 0.5mg\n\nLike all medications, Pramipexole may cause side effects in some individuals. Many side effects are mild and improve as the body adjusts to treatment.\n\nCommon Side Effects\nNausea\nDizziness\nDrowsiness\nDry mouth\nConstipation\nFatigue\nHeadache\nSerious Side Effects\n\nSeek immediate medical attention if you experience:\n\nHallucinations\nSevere dizziness\nFainting\nSudden sleep episodes\nUnusual behavior changes\nSwelling of hands or feet\n\nSome patients may experience impulse control problems such as compulsive gambling or increased urges. Inform your doctor immediately if behavioral changes occur.\n\nPrecautions Before Using Pramipexole 0.5mg\n\nBefore starting treatment, tell your doctor if you have:\n\nKidney disease\nLow blood pressure\nHeart problems\nMental health disorders\nSleep disorders\nHistory of hallucinations\n\nPatients taking Pramipexole should avoid activities requiring alertness, such as driving, until they know how the medicine affects them.\n\nAlcohol consumption may increase drowsiness and dizziness and should be avoided or limited.\n\nDrug Interactions\n\nPramipexole 0.5mg may interact with other medications, including:\n\nSedatives\nAntidepressants\nAntipsychotic medicines\nSleeping pills\nBlood pressure medications\n\nAlways share your complete medication list with your healthcare provider to prevent harmful interactions.\n\nWhy Choose Pramipexole 0.5mg?\n\nMany healthcare professionals prefer Pramipexole because it provides:\n\nEffective dopamine receptor stimulation\nSymptom relief in Parkinson’s disease\nImproved sleep in RLS patients\nBetter movement control\nEnhanced daily functioning\n\nThe medicine can play an important role in long-term neurological care when used under proper medical supervision.\n\nStorage Instructions\n\nStore Pramipexole:\n\nIn a cool and dry place\nAway from direct sunlight\nBelow recommended room temperature\nOut of reach of children\n\nDo not use expired medicine.\n\nFrequently Asked Questions\nWhat is Pramipexole 0.5mg used for?\n\nIt is mainly used to treat Parkinson’s disease and Restless Legs Syndrome.\n\nHow long does Pramipexole take to work?\n\nSome patients notice improvement within a few days, while full benefits may take several weeks depending on the condition.\n\nCan Pramipexole cause sleepiness?\n\nYes, drowsiness and sudden sleep episodes may occur in some individuals.\n\nIs Pramipexole safe for long-term use?\n\nYes, many patients use it long-term under regular medical supervision.\n\nCan I stop taking Pramipexole suddenly?\n\nNo, sudden discontinuation may worsen symptoms. Always consult your doctor before stopping treatment.\n\nConclusion\n\nPramipexole 0.5mg is an effective medication for managing symptoms of Parkinson’s disease and Restless Legs Syndrome. By stimulating dopamine receptors in the brain, it helps improve movement, reduce tremors, relieve muscle stiffness, and support better sleep quality.", "price": 98.0, "discountamount": 30.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "RLS", "day", "life", "food", "brain", "EMAIL", "Order", "water", "0.5 mg", "4.5 mg", "tablet", "tremors", "quality", "bedtime", "symptoms", "Benefits", "0.125 mg", "patients", "Research", "response", "Parkinson", "stiffness", "PRAMIXOLE", "same time", "next dose", "treatment", "conditions", "double dose", "three doses", "progression", "bloodstream", "information", "Pramipexole", "sterispharma", "coordination", "sterisonline", "Key Features", "Introduction", "CALL/WHATSAPP", "slow movement", "0.50 mg dosage", "Administration", "Initial Dosage", "Flexible Dosing", "dopamine agonist", "maintenance dose", "regular schedule", "individual needs", "movement control", "Disease Management", "significant relief", "Maintenance Dosage", "dopamine receptors", "precise adjustments", "typical starting dose", "neuroprotective effects", "Improved Motor Function", "uncomfortable sensations", "Neuroprotective Properties", "consistent medication levels", "Restless Legs Syndrome Relief" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1876, "imageuri": "https://productimages.withfloats.com/actual/666ad76c2d43284d727349be.jpg", "tileimageuri": "https://productimages.withfloats.com/tile/666ad76c2d43284d727349be.jpg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-13T11:25:31.913Z", "updatedon": "2026-05-11T07:49:55.113Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//pramipexole-0-5mg/1876", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "PRAMIXOLE 0.50 ", "category": "NEUROLOGY RANGE", "tags": [ "Pramipexole 0.5 mg Tablets", "Buy Pramipexole 0.5 mg Tablets Online", "Pramipexole 0.5 mg Medicine for Parkinson’s Disease", "Pramipexole Tablets for Restless Legs Syndrome", "Pramipexole 0.5 mg Neurology Medicine", "Pramipexole Tablets for Dopamine Deficiency Treatment", "Pramipexole 0.5 mg Prescription Medicine", "Pramipexole 0.5 mg Tablet Product Image", "Best Pramipexole Tablets for Parkinson’s Treatment", "Neurological Medicine Pramipexole 0.5 mg", "Buy Pramipexole Tablets Online", "Pramipexole 0.5 mg Tablets for Restless Leg Syndrome", "Pramipexole Tablets for Parkinson’s Symptom Management", "Dopamine Agonist Medicine Pramipexole 0.5 mg" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "666abe06cee93a1bbc383645", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "nicoumalone 2mg", "description": "NICOMALOM 2 \nNICOMALOM 2 features Nicoumalone, also known as Acenocoumarol, as its active ingredient in a 2mg tablet formulation. This medication belongs to the coumarin class of anticoagulants, which work by interfering with the liver's production of vitamin K-dependent clotting factors like II, VII, IX, and X. Unlike newer direct oral anticoagulants, NICOMALOM 2 offers a well-established profile with adjustable dosing based on individual INR monitoring, ideal for personalized treatment plans. Each tablet is crafted for easy oral administration, typically once daily, ensuring consistent blood thinning without the need for injections.\n​\n\nThe formulation ensures rapid absorption, with peak effects within hours, allowing for effective clot prevention in high-risk scenarios. Steris Healthcare emphasizes quality manufacturing standards, making NICOMALOM 2 suitable for adults managing chronic conditions or post-surgical recovery. Its compact packaging of 10 tablets per strip supports convenient storage and portability for ongoing therapy.\n​\n\nKey Uses\nNICOMALOM 2 excels in preventing and treating thromboembolic disorders where blood clots pose immediate dangers. Primary applications include deep vein thrombosis (DVT), where clots form in deep leg veins, and pulmonary embolism (PE), a potentially fatal blockage in lung arteries. Physicians also prescribe it to reduce stroke risk in patients with atrial fibrillation, a common irregular heartbeat that promotes clot formation in the heart.\n​\n\nBeyond these, NICOMALOM 2 prevents clots after surgeries like hip or knee replacements, or in those with mechanical heart valves. It supports prophylaxis in recurrent clotting episodes, ensuring smoother blood flow and oxygen delivery to vital organs. For patients in Jaipur and Rajasthan facing high incidences of cardiovascular issues due to lifestyle factors, this medication provides targeted protection tailored to regional healthcare needs.\n​\n\nMechanism of Action\nNICOMALOM 2 disrupts the clotting cascade by blocking vitamin K epoxide reductase, an enzyme essential for regenerating vitamin K. This inhibition halts the activation of prothrombin and other coagulation factors, thinning the blood and preventing new clot formation while allowing existing ones to dissolve naturally. The result is improved vascular patency, reducing symptoms like leg swelling in DVT or breathlessness in PE.\n​\n\nTherapeutic levels are maintained through regular INR testing, typically targeting 2.0-3.0 for most indications, which differentiates it from fixed-dose alternatives. This precise control minimizes over-anticoagulation risks, making it suitable for long-term use in diverse patient profiles, including the elderly under careful supervision.\n​\n\nKey Benefits\nPatients using NICOMALOM 2 experience significant reductions in clot-related hospitalizations, with studies showing up to 80% lower stroke incidence in atrial fibrillation cases. Its oral convenience enhances adherence compared to injectables, promoting better quality of life for those with mobility limitations post-surgery. Cost-effectiveness positions it as an accessible option in India's pharmaceutical market, especially for Steris Healthcare clients optimizing SEO-driven healthcare content.\n​\n\nAdditional advantages include reversibility with vitamin K administration in emergencies and compatibility with dietary adjustments for stable INR. For pharmaceutical marketers, NICOMALOM 2's established safety data supports strong branding in neurology and cardiology segments, driving patient trust and repeat prescriptions.\n​\n\nBenefit\tDescription\tClinical Impact \n​\nStroke Prevention\tLowers risk in atrial fibrillation by 60-70%\tFewer neurological emergencies\nPost-Surgical Protection\tReduces thromboembolism after orthopedic procedures\tShorter recovery times\nDVT/PE Management\tHalts clot progression effectively\tImproved mobility and oxygenation\nLong-Term Safety\tAdjustable dosing via INR monitoring\tSustained therapy without frequent switches\nAffordability\tCompetitive pricing in Indian market\tHigh accessibility for diverse demographics\nPotential Side Effects\nWhile effective, NICOMALOM 2 carries bleeding risks as its primary concern, including easy bruising, gum bleeding, or prolonged cuts. Common gastrointestinal issues like nausea, vomiting, or diarrhea affect some users, often manageable by taking with food. Less frequent effects encompass hair loss, skin rashes, or itching, which typically resolve with dose adjustments.\n​\n\nRare but serious reactions involve heavy menstrual bleeding, nosebleeds, or internal hemorrhage signaled by black stools or blood in urine—prompt medical attention is crucial. Elderly patients or those with liver/kidney impairment face heightened sensitivity, necessitating baseline assessments. Interactions with antibiotics, NSAIDs, or vitamin K-rich foods like spinach can amplify effects, underscoring the need for holistic patient education.\n​\nSide Effect Category\tExamples\tManagement Tips \n​\nCommon (Mild)\tBruising, nausea, diarrhea\tTake with meals; monitor diet\nSerious (Bleeding)\tNosebleeds, heavy periods, wounds\tSeek immediate care; INR checks\nRare\tHair loss, rash, appetite loss\tDose tweak; symptomatic relief\nDrug/Food Interactions\tWarfarin-like potentiators, greens\tInform doctor of all intake\nDosage and Safety Precautions\nStandard initial dosing starts at 2-4 mg daily, titrated per INR response, often 1-10mg maintenance. Children and the elderly require caution with lower starts. Avoid abrupt stops to prevent rebound clotting; inform surgeons/dentists pre-procedure. Pregnant or breastfeeding women should consult alternatives due to fetal risks.\n​\nRegular prothrombin time tests ensure efficacy, with lifestyle advice like avoiding contact sports minimizing injury. Store at room temperature, away from moisture.\n​\nConclusion\nNICOMALOM 2 delivers robust anticoagulation for clot prevention, balancing potent benefits against manageable risks through vigilant monitoring. For patients and healthcare providers in pharmaceutical hubs like Jaipur, it remains a cornerstone therapy, enhancing outcomes in DVT, PE, and beyond. Always prioritize professional guidance for optimal results.", "price": 227.0, "discountamount": 68.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "DVT", "food", "heart", "water", "Doses", "EMAIL", "tablet", "patients", "Benefits", "NICOMALOM", "synthesis", "same time", "Nicoumalone", "2 mg dosage", "INR) levels", "information", "Introduction", "Key Features", "sterisonline", "initial dose", "sterispharma", "long-term use", "CALL/WHATSAPP", "Administration", "Initial Dosage", "target INR range", "prothrombin time", "most indications", "maintenance dose", "affordable option", "careful monitoring", "Maintenance Dosage", "chronic conditions", "pulmonary embolism", "healthcare provider", "regular blood tests", "atrial fibrillation", "Standardized Dosing", "precise adjustments", "deep vein thrombosis", "blood clot formation", "Long-Term Management", "thromboembolic events", "Stroke Risk Reduction", "typical starting dose", "regular INR monitoring", "consistent blood levels", "optimal anticoagulation", "thromboembolic disorders", "Thromboembolism Prevention", "International Normalized Ratio", "potent anticoagulant medication", "vitamin K-dependent clotting factors" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1860, "imageuri": "https://productimages.withfloats.com/actual/666abe098b71a2cb2d7d3c68.png", "tileimageuri": "https://productimages.withfloats.com/tile/666abe098b71a2cb2d7d3c68.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-13T09:38:14.673Z", "updatedon": "2026-03-13T05:57:23.788Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//nicoumalone-2mg/1860", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "NICOMALOM 2 ", "category": "NEUROLOGYRANGE", "tags": [ "nicoumalone 2mg uses", "nicoumalone tablet", "nicoumalone tablets side effects", "nicoumalone tablet dosage", "nicoumalone drug interactions" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "6662e3b87247ae19c482b97c", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Enzalutamide 40mg", "description": "Enzalutamide 40 mg capsules represent a breakthrough in targeted therapy for advanced prostate cancer, particularly in metastatic castration-resistant prostate cancer (mCRPC) and metastatic castration-sensitive prostate cancer (mCSPC). This second-generation androgen receptor inhibitor works by disrupting multiple steps in the androgen signaling pathway, offering patients a chance to slow disease progression, reduce tumor burden, and extend survival even after other treatments fail. Administered as a once-daily oral capsule, enzalutamide 40 mg provides four capsules per day (total 160 mg), making it convenient for long-term use in clinical settings where hormone therapy alone proves insufficient.​\n\nPatients often turn to enzalutamide when facing rising PSA levels despite androgen deprivation therapy (ADT), experiencing bone pain, or dealing with cancer spread to lymph nodes or distant sites. Its high affinity for androgen receptors—5-8 times stronger than first-generation antiandrogens like bicalutamide—ensures potent blockade without agonist activity, translating to real-world benefits like delayed chemotherapy needs and improved quality of life during treatment.​\n\nProduct Use and Indications\nEnzalutamide 40 mg primarily treats metastatic castration-resistant prostate cancer (mCRPC) in patients previously treated with docetaxel or progressing despite ADT. The FDA and EMA approvals extend to non-metastatic CRPC (nmCRPC) with high-risk biochemical recurrence and metastatic castration-sensitive prostate cancer (mCSPC) alongside ADT, based on landmark trials like AFFIRM, PREVAIL, PROSPER, and ARCHES.​\n\nKey uses include:\n\nSlowing tumor growth in hormone-refractory stages by inhibiting androgen-driven proliferation.\n\nReducing skeletal-related events like fractures or spinal cord compression in bone metastases.\n\nDelaying progression to chemotherapy in pre-chemotherapy mCRPC, with PREVAIL showing 17-month median radiographic progression-free survival (rPFS) versus 4 months for placebo.​\n\nIn mCSPC, ARCHES trial data demonstrated 61% risk reduction in progression or death when combined with ADT. Clinicians monitor PSA response (≥50% decline in 70-80% of patients) and imaging every 3 months to assess efficacy.​\n\nMechanism of Action\nEnzalutamide 40 mg exerts a threefold blockade on androgen receptor (AR) signaling: it competitively inhibits androgen binding to AR (with affinity rivaling dihydrotestosterone), prevents nuclear translocation of the ligand-receptor complex, and disrupts DNA binding and coactivator recruitment at androgen response elements. This comprehensive inhibition downregulates oncogenes like TMPRSS2-ERG fusion genes common in prostate cancer, inducing apoptosis and halting cell proliferation without lowering systemic testosterone levels.​\n\nUnlike earlier antiandrogens, enzalutamide avoids partial agonist effects, ensuring pure antagonism even in AR-overexpressing tumors. Its active metabolite, N-desmethyl enzalutamide (via CYP2C8), contributes 30% to activity, with steady-state levels achieved in 4 weeks.​\n\nKey Benefits\nExtended Progression-Free Survival: In PREVAIL (pre-chemo mCRPC), median overall survival reached 32.4 months versus 30.2 for placebo; PROSPER (nmCRPC) delayed metastasis by 22 months.​\n\nPSA Response and Tumor Shrinkage: 78% PSA90 response rate; radiographic responses in 29% with measurable disease.​\n\nQuality of Life Preservation: Delays pain progression (hazard ratio 0.40) and chemotherapy (by 17 months), maintaining daily function.​\n\nBone Protection: Reduces fractures by 30% in high-risk patients via AR inhibition in osteoblasts.​\n\nCombination Synergy: Enhances ADT efficacy in mCSPC, cutting death risk by 33% per ARCHES.​\n\nThese benefits position enzalutamide 40 mg as a cornerstone in modern prostate cancer protocols, especially for fit patients tolerating oral therapy.​\n\nSide Effects\nEnzalutamide 40 mg carries a manageable profile, with most effects dose-related and reversible upon discontinuation.\n\nCommon Side Effects\nFatigue/Asthenia (34-50%): Often mild, peaking in first months; rest and nutrition help.\n\nArthralgia/Myalgia (14-21%): Joint/muscle pain managed with NSAIDs.\n\nHot Flashes (20%): Androgen blockade mimic; hydration aids.\n\nHeadache/Dizziness (12-19%): Transient; avoid driving if severe.\n\nHypertension (6-13%): Monitor BP monthly; antihypertensives as needed.\n\nGI Issues (diarrhea 12%, nausea 11%): Antiemetics support compliance.​\n\nSerious Side Effects\nSeizures (0.9%): Highest risk in epileptics or brain mets; EEG baseline, avoid triggers.\n\nPosterior Reversible Encephalopathy (PRES): Rare (<0.1%); headache, confusion—MRI confirms.\n\nFalls/Fractures (15% increased risk): Due to weakness/falls; DEXA scans recommended.\n\nCardiac Events (2-5%): MI/arrhythmias; ECG monitoring in CVD history.\n\nHepatic Injury (1%): ALT/AST elevation; monthly labs first 3 months.​\n\nDiscontinuation occurs in 8-10%; supportive care mitigates most.​\n\nDosage and Administration\nStandard dose: 160 mg (four 40 mg capsules) once daily, with or without food. Swallow intact; no crushing. Adjust for CYP2A4 inducers (e.g., rifampin—increase to 240 mg) or strong inhibitors (reduce to 80 mg). Continue until progression/toxicity; no dose interruptions beyond 28 days without reassessment.​\n\nPrecautions and Monitoring\nContraindicated in pregnancy (teratogenic; absolute contraception for men/ partners). Screen for seizure history; CYP2C8/3A4 interactions (e.g., ketoconazole). Baseline LFTs, PSA, testosterone; imaging q8-12 weeks. Elderly (>75) monitor falls.​\nConclusion\nEnzalutamide 40 mg stands as a transformative therapy, empowering prostate cancer patients with prolonged control over aggressive disease through precise AR inhibition. Balancing robust efficacy—evidenced by landmark trials delaying metastasis and death—with proactive side effect management, it enhances survival and daily living. Patients achieve meaningful milestones, from family events to travel, underscoring its role in personalized oncology. Consult oncologists for integration into care plans, ensuring optimal outcomes in this challenging journey.\nEmail: info@sterispharma.com / contact@sterispharma.com\nCall/WhatsApp: 7877551268, 7849827488\n\n\n\n\n\n\n\n\n", "price": 10781.0, "discountamount": 3235.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "Call", "Email", "doctor", "product", "fatigue", "WhatsApp", "treatment", "schedules", "ENZULAMIDE", "monitoring", "hot flashes", "information", "sterisonline", "hypertension", "sterispharma", "prostate cancer", "Enzalutamide 40mg", "prescribed dosages", "androgen receptors", "cancer cell growth", "Common side effects", "comprehensive guidance" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1527, "imageuri": "https://productimages.withfloats.com/actual/667d2a356c582d228f45a098.png", "tileimageuri": "https://productimages.withfloats.com/tile/667d2a356c582d228f45a098.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-07T10:40:56.587Z", "updatedon": "2026-03-16T08:18:18.117Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//enzalutamide-40mg/1527", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "ENZULAMIDE 40", "category": "Oncology", "tags": [ "enzalutamide 40 mg side effects", "enzalutamide 40 mg brands in india", "enzalutamide 40 mg uses in hindi", "enzalutamide 40 mg dosage", "advanced prostate cancer", "prostate cancer", "metastatic castration-resistant prostate cancer", "enzalutamide 40mg tablets", "enzalutamide 40 mg capsule", "enzalutamide 40mg uses", "enzalutamide 40mg dosage", "enzalutamide 40mg price in india", "enzalutamide 40mg composition", "enzalutamide 40mg working mechanism", "enzalutamide 40mg side effects", "enzalutamide 40mg benefits", "enzalutamide 40mg drug information", "enzalutamide 40mg therapy details", "enzalutamide 40mg oral capsule", "enzalutamide 40mg treatment option", "enzalutamide 40mg pharmaceutical uses", "enzalutamide 40mg branded tablets", "enzalutamide 40mg generic medicine", "enzalutamide 40mg manufacturer in india", "what is enzalutamide 40mg used for", "how enzalutamide 40mg works", "is enzalutamide 40mg safe", "enzalutamide 40mg tablet information", "enzalutamide 40mg dosage guidelines" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "662f3f35e2fa911c8c2923c3", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "RISPERITIME PLUS ", "description": "RISPERITIME PLUS \nRisperidone (2mg), Trihexyphenidyl (2mg)\nRisperitime Plus is a combination medication featuring Risperidone (2mg) and Trihexyphenidyl (2mg). It is primarily used to manage symptoms of psychiatric disorders such as schizophrenia and bipolar disorder. Risperidone helps in stabilizing mood and reducing hallucinations, while Trihexyphenidyl controls drug-induced movement disorders, ensuring comprehensive management of symptoms. This medication should be used under strict medical supervision due to potential side effects and interactions. Always consult your healthcare provider for personalized advice and treatment plans.\nFor further information:\nEmail: info@sterispharma.com / contact@sterispharma.com\nCall/WhatsApp: 7877551268, 7849827488\nBuy Now: \n", "price": 65.0, "discountamount": 20.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "mood", "symptoms", "Risperidone", "interactions", "schizophrenia", "hallucinations", "Trihexyphenidyl", "treatment plans", "RISPERITIME PLUS", "bipolar disorder", "personalized advice", "healthcare provider", "psychiatric disorders", "potential side effects", "combination medication", "comprehensive management", "strict medical supervision", "drug-induced movement disorders" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 777, "imageuri": "https://productimages.withfloats.com/actual/662f3f37e00b62b2b7823f17.jpeg", "tileimageuri": "https://productimages.withfloats.com/tile/662f3f37e00b62b2b7823f17.jpeg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-04-29T06:33:25.05Z", "updatedon": "2026-03-12T11:43:05.048Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//risperitime-plus-/777", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "Risperidone (2mg), Trihexyphenidyl (2mg)", "category": "NEUROLOGYRANGE", "tags": [], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "662b9c5ce6d2b71ee071e9eb", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "IMATIFLOW 400 ", "description": "IMATIFLOW 400 \nImatinib IP (400mg)\nIMATIFLOW 400, containing Imatinib IP at 400mg strength, is a vital medication in oncology, primarily used to treat certain types of leukemia and gastrointestinal stromal tumors (GISTs). By targeting specific proteins involved in cancer cell growth, IMATIFLOW 400 helps to slow down or inhibit the progression of these diseases. It is often a crucial part of personalized cancer treatment plans, prescribed under strict medical supervision, and requires regular monitoring for optimal therapeutic outcomes.", "price": 1949.0, "discountamount": 585.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "GISTs", "types", "diseases", "leukemia", "oncology", "IMATIFLOW", "Imatinib IP", "progression", "crucial part", "400mg strength", "vital medication", "specific proteins", "regular monitoring", "cancer cell growth", "strict medical supervision", "optimal therapeutic outcomes", "gastrointestinal stromal tumors", "personalized cancer treatment plans" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 768, "imageuri": "https://productimages.withfloats.com/actual/662b9c5e0f245019b82ae160.png", "tileimageuri": "https://productimages.withfloats.com/tile/662b9c5e0f245019b82ae160.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-04-26T12:21:48.769Z", "updatedon": "2026-03-12T12:05:50.372Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//imatiflow-400-/768", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "Imatinib IP (400mg)", "category": "NEPHROLOGYRANGE", "tags": [], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false } ], "hasmoreitems": false, "isapirequest": false, "totalresults": 27, "query": null, "floatingpoint": null }